India-Brazil Forge Ahead with MoU on Pharma and Medical Regulation

India and Brazil have signed a pivotal Memorandum of Understanding (MoU) to bolster bilateral cooperation in regulating pharmaceutical and medical products, exchanged on February 21, 2026, at Hyderabad House. The agreement between India’s Central Drugs Standard Control Organisation (CDSCO) and Brazil’s Health Regulatory Agency (ANVISA) was formally signed by ANVISA Director-President Mr. Leandro Safatle and Indian Ambassador to Brazil Shri Dinesh Bhatia, in the presence of Prime Minister Shri Narendra Modi and Brazilian President H.E. Luiz Inácio Lula da Silva. This move signifies a strategic leap in harmonizing regulatory frameworks between two Global South powerhouses.
The MoU creates a robust platform for exchanging information and expertise on medical
products, encompassing pharmaceutical ingredients, drugs, biological products, and medical devices. It seeks to align regulatory practices, deepen mutual comprehension of oversight systems, and enable coordinated monitoring to uphold safety and efficacy standards. By fostering this synergy, both nations aim to fortify supply chains, disseminate best regulatory practices, and enhance access to affordable, high-quality healthcare solutions for their populations.
This pact underscores a shared dedication to delivering safe, effective medicines amid
growing global health demands. It builds on longstanding India-Brazil health sector ties,
complementing existing bilateral channels and amplifying collaboration in pharmaceuticals
and medical technologies. As leading voices from the Global South, the partnership
highlights their aligned priorities in equitable healthcare advancement.
Key focus areas include information sharing, capacity building, and joint efforts in regulatory matters, all while adhering to respective national laws. The initiative promises to elevate public health outcomes through innovative exchanges and strengthened oversight, mitigating risks in product development and distribution.
The MoU exchange not only cements India-Brazil relations but also unlocks fresh
opportunities in the health and pharma domains. It positions both countries to lead in
responsible regulation, ensuring resilient systems that support innovation and accessibility
worldwide. As global challenges like pandemics persist, this collaboration exemplifies
proactive diplomacy, driving mutual prosperity and healthier futures for millions.